Wikipedia

ANGPTL8

ANGPTL8 (also known as lipasin, previously betatrophin) is a protein that in humans is encoded by the C19orf80 gene.

ANGPTL8
Identifiers
AliasesANGPTL8, PRO1185, PVPA599, RIFL, TD26, C19orf80, Betatrophin, angiopoietin like 8
External IDsOMIM: 616223; MGI: 3643534; HomoloGene: 83285; GeneCards: ANGPTL8; OMA:ANGPTL8 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

55908

624219

Ensembl

ENSG00000130173

ENSMUSG00000047822

UniProt

Q6UXH0

Q8R1L8

RefSeq (mRNA)

NM_018687

NM_001080940

RefSeq (protein)

NP_061157

NP_001074409

Location (UCSC)Chr 19: 11.24 – 11.24 MbChr 9: 21.75 – 21.75 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Gene

edit

The ANGPTL8 gene lies on mouse chromosome 9 (gene symbol: Gm6484) and on human chromosome 19 (gene symbol: C19orf80).

Discovery

edit

The ANGPTL8 gene was discovered in 2012 as RIFL, Lipasin, and ANGPTL8.[5][6] [7] In 2013 it was suggested by Melton and Yi from Harvard that ANGPTL8 promotes mouse pancreatic islet cell proliferation. These results led the authors to propose an alternative name for ANGPTL8, betatrophin.[8] However, the link between ANGPTL8 and islet proliferation was quickly proven false by other researchers.[9] In fact, in December 2016 the original paper by Melton and Yi was retracted, putting the link between ANGPTL8 and islets cells to rest. Nevertheless, the name betatrophin continues to be used. Given the homology of ANGPTL8 with ANGPTL4 and ANGPTL3, and considering that ANGPTL8 does not promote beta cell proliferation, the name betatrophin should be abandoned in favor of ANGPTL8.[10]

Function

edit

The encoded 22 kDa protein contains an N-terminal secretion signal and two coiled-coil domains and is a member of the angiopoietin-like (ANGPTL) protein family. However, in contrast to other ANGPTL proteins, ANGPTL8 lacks the C-terminal fibrinogen-like domain, and therefore it is an atypical member of the ANGPTL family.[11] ANGPTL8 has been shown to form complexes with ANGPTL3 with an apparent stoichiometry of 3:1 of ANGPTL3 to ANGPTL8 respectively.[12] Formation of these complexes appears to require intracellular co-folding as mixing of ANGPTL8 and ANGPTL3 extracellularly does not result in complex formation.[13] ANGPTL8 is expressed in the hepatic tissue and secreted into circulation, in order for the efficient secretion of ANGPTL8 it must form a complex with ANGPTL3.[13] ANGPTL8 alone shows little inhibitory capacity and must form a complex with ANGPTL3 to inhibit the enzyme Lipoprotein lipase (LPL) and has been shown to greatly promote the ability of ANGPTL3 to inhibit LPL.[13][14] In mice ANGPTL8 is secreted by the liver and by adipose tissue, hepatic overexpression of ANGPTL8 causes elevation of circulating Triglyceride levels.[5][6]

Despite having elevated post-heparin plasma LPL activity, mice lacking ANGPTL8 exhibit markedly decreased uptake of Very low-density lipoprotein-derived fatty acids into white adipose tissue (WAT).[15] The defect in fatty acids uptake by WAT in ANGPTL8-null mice is likely due to the enhanced fatty acid uptake by the heart and skeletal muscle, because of the elevated LPL activity in these two tissues,[16] as suggested by the ANGPTL3-4-8 model.[17]

ANGPTL8 was proposed to increase the rate at which beta-cells undergo cell division. Injection of mice with ANGPTL8 cDNA lowered blood sugar (i.e. hypoglycemia), presumably due to action at the pancreas. However, treatment of human islets with ANGPTL8 is unable to increase beta-cell division.[18] Furthermore, studies in ANGPTL8 knock-out mice do not support a role of ANGPTL8 in controlling beta cell growth, yet point to a clear role in regulating plasma triglyceride levels.[19] Based on these studies, it is fairly safe to say that the notion that ANGPTL8 promotes beta cell expansion is dead, which was made official by the retraction of the original paper.[18][20] Deletion of ANGPTL8 does not seem to impact glucose and insulin tolerance in mice.[15]

Structure

edit

Three dimensional structure of none of the members of Angiopoietin like proteins (ANGPTLs) is available up until now.[when?] However, the structure of ANGPTL8 was predicted by homology modeling and is also reported in literature.[21] It consists of alpha helices and its sequence show high similarity with the coiled-coil domains of ANGPTL3 and ANGPTL4.

Pathway

edit

The ANGPTL8 regulatory pathway has been constructed recently by integrating the information of its know transcription factors which is available at WikiPathways data repository with the pathway id WP3915.[22]

Clinical significance

edit

It was hoped that ANGPTL8 or its homolog in humans may provide an effective treatment for type 2 diabetes and perhaps even type I diabetes.[8] Unfortunately, since new data have greatly called into question the ability of ANGPTL8 to increase beta-cell replication, its potential use as a therapy for type 2 diabetes is limited.[19] Inhibition of ANGPTL8 represents a possible therapeutic strategy for hypertriglyceridemia.[16]

References

edit
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000130173 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000047822 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b Zhang R (August 2012). "Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels". Biochemical and Biophysical Research Communications. 424 (4): 786–792. doi:10.1016/j.bbrc.2012.07.038. PMID 22809513.
  6. ^ a b Ren G, Kim JY, Smas CM (August 2012). "Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism". American Journal of Physiology. Endocrinology and Metabolism. 303 (3): E334–E351. doi:10.1152/ajpendo.00084.2012. PMC 3423120. PMID 22569073.
  7. ^ Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, et al. (November 2012). "Atypical angiopoietin-like protein that regulates ANGPTL3". Proceedings of the National Academy of Sciences of the United States of America. 109 (48): 19751–19756. Bibcode:2012PNAS..10919751Q. doi:10.1073/pnas.1217552109. PMC 3511699. PMID 23150577.
  8. ^ a b Yi P, Park JS, Melton DA (May 2013). "Betatrophin: a hormone that controls pancreatic β cell proliferation". Cell. 153 (4): 747–758. doi:10.1016/j.cell.2013.04.008. PMC 3756510. PMID 23623304. (Retracted, see doi:10.1016/j.cell.2016.12.017, PMID 28038792,  Retraction Watch)
  9. ^ Gusarova V, Alexa CA, Na E, Stevis PE, Xin Y, Bonner-Weir S, et al. (October 2014). "ANGPTL8/betatrophin does not control pancreatic beta cell expansion". Cell. 159 (3): 691–696. doi:10.1016/j.cell.2014.09.027. PMC 4243040. PMID 25417115.
  10. ^ Zhang R, Abou-Samra AB (March 2013). "Emerging roles of Lipasin as a critical lipid regulator". Biochemical and Biophysical Research Communications. 432 (3): 401–405. doi:10.1016/j.bbrc.2013.01.129. PMID 23415864.
  11. ^ Fu Z, Yao F, Abou-Samra AB, Zhang R (January 2013). "Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family". Biochemical and Biophysical Research Communications. 430 (3): 1126–1131. doi:10.1016/j.bbrc.2012.12.025. PMID 23261442.
  12. ^ Chen YQ, Pottanat TG, Siegel RW, Ehsani M, Qian YW, Zhen EY, et al. (August 2020). "Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids". Journal of Lipid Research. 61 (8): 1203–1220. doi:10.1194/jlr.ra120000781. PMC 7397750. PMID 32487544.
  13. ^ a b c Chi X, Britt EC, Shows HW, Hjelmaas AJ, Shetty SK, Cushing EM, et al. (October 2017). "ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase". Molecular Metabolism. 6 (10): 1137–1149. doi:10.1016/j.molmet.2017.06.014. PMC 5641604. PMID 29031715.
  14. ^ Haller JF, Mintah IJ, Shihanian LM, Stevis P, Buckler D, Alexa-Braun CA, et al. (June 2017). "ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance". Journal of Lipid Research. 58 (6): 1166–1173. doi:10.1194/jlr.M075689. PMC 5454515. PMID 28413163.
  15. ^ a b Wang Y, Quagliarini F, Gusarova V, Gromada J, Valenzuela DM, Cohen JC, et al. (October 2013). "Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis". Proceedings of the National Academy of Sciences of the United States of America. 110 (40): 16109–16114. Bibcode:2013PNAS..11016109W. doi:10.1073/pnas.1315292110. PMC 3791734. PMID 24043787.
  16. ^ a b Fu Z, Abou-Samra AB, Zhang R (December 2015). "A lipasin/Angptl8 monoclonal antibody lowers mouse serum triglycerides involving increased postprandial activity of the cardiac lipoprotein lipase". Scientific Reports. 5: 18502. Bibcode:2015NatSR...518502F. doi:10.1038/srep18502. PMC 4685196. PMID 26687026.
  17. ^ Zhang R (April 2016). "The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking". Open Biology. 6 (4): 150272. doi:10.1098/rsob.150272. PMC 4852456. PMID 27053679.
  18. ^ a b Jiao Y, Le Lay J, Yu M, Naji A, Kaestner KH (April 2014). "Elevated mouse hepatic betatrophin expression does not increase human β-cell replication in the transplant setting". Diabetes. 63 (4): 1283–1288. doi:10.2337/db13-1435. PMC 3964501. PMID 24353178.
  19. ^ a b Gusarova V, Alexa CA, Na E, Stevis PE, Xin Y, Bonner-Weir S, et al. (October 2014). "ANGPTL8/betatrophin does not control pancreatic beta cell expansion". Cell. 159 (3): 691–696. doi:10.1016/j.cell.2014.09.027. PMC 4243040. PMID 25417115.
  20. ^ Stewart AF (April 2014). "Betatrophin versus bitter-trophin and the elephant in the room: time for a new normal in β-cell regeneration research". Diabetes. 63 (4): 1198–1199. doi:10.2337/DB14-0009. PMC 3964499. PMID 24651805.
  21. ^ Siddiqa A, Ahmad J, Ali A, Paracha RZ, Bibi Z, Aslam B (April 2016). "Structural characterization of ANGPTL8 (betatrophin) with its interacting partner lipoprotein lipase". Computational Biology and Chemistry. 61: 210–220. doi:10.1016/j.compbiolchem.2016.01.009. PMID 26908254.
  22. ^ Siddiqa A, Cirillo E, Tareen SH, Ali A, Kutmon M, Eijssen LM, et al. (October 2017). "Visualizing the regulatory role of Angiopoietin-like protein 8 (ANGPTL8) in glucose and lipid metabolic pathways". Genomics. 109 (5–6): 408–418. doi:10.1016/j.ygeno.2017.06.006. PMID 28684091.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=ANGPTL8&oldid=1254064679"